The Online Investor
Catalyst Biosciences Inc (CBIO)

Catalyst Biosciences is a clinical-stage biotechnology company focused on developing medicines to address hematology indications. Co.'s principal program is a coagulation Factor VIIa protease variant, marzeptacog alfa (activated), for the treatment of hemophilia and to facilitate surgery in hemophilia. Co.'s second hemophilia program is a Factor IX protease variant, CB 2679d/ISU304, a subcutaneously dosed Factor IX drug for the prophylactic treatment of individuals with hemophilia B. Co. is also exploring licensing opportunities for its pre-clinical anti-C3 protease development candidate, CB 2782, and its anti-C3 protease program for Dry Age-Related Macular Degeneration.
Company Name: 
Catalyst Biosciences Inc
Number of ETFs Holding CBIO: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
96th percentile
(ranked higher than approx. 96% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Catalyst Biosciences Inc (CBIO) Page | The Online Investor Page |

Copyright © 1998 - 2018, All Rights Reserved Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.